Mind Medicine (MNMD) said Thursday the UK's Medicines and Healthcare Products Regulatory Agency granted an Innovation Passport designation for its MM120 orally disintegrated table, which is currently in clinical development for the treatment of generalized anxiety disorder.
The designation allows access to tools to support the design, development, and approvals process in the UK, and provides opportunities for enhanced regulatory and other stakeholder input, the biopharmaceutical company said.
The passport is considered an "entry point" to the Innovative Licensing and Access Pathway, a program that seeks to speed up patients' access to new medicines, the company said.
Shares of the Mind Medicine fell 3.6% in recent Thursday trading.
Price: 7.21, Change: -0.27, Percent Change: -3.61
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。